Advanz Agrees Cut-Price Deal For Troubled Correvio Pharma
Firm Also Signs Agreement For UCB Portfolio
With a clear plan to move on niche and differentiated generics, complex specialty and value-added medicines, Advanz Pharma has agreed to buy debt-ridden Correvio Pharma and the rights to a portfolio from UCB, at the same time as shareholders opted to move to delist the company’s shares.
